

Convergent molecular defects underpin diverse neurodegenerative diseases

George K Tofaris¹, Noel J Buckley²

¹Nuffield Department of Clinical Neurosciences, Level 6, West Wing, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU

²Department of Psychiatry, Warneford Hospital, Warneford Lane University of Oxford, Oxford OX3 7JX

Correspondence: george.tofaris@ndcn.ox.ac.uk

Word Count in Main Text: 4,806

Number of References: 122 (50 to be included in the main text)

Abstract

In our ageing population, neurodegenerative disorders carry an enormous personal, societal and economic burden. Although, neurodegenerative diseases are often thought of as clinico-pathological entities, increasing evidence suggests a considerable overlap in the molecular underpinnings of their pathogenesis. Such overlapping biological processes include the handling of misfolded proteins, defective organelle trafficking, RNA processing, synaptic health and neuroinflammation. Collectively but in different proportions, these biological processes in neurons or non-neuronal cells lead to regionally distinct patterns of neuronal vulnerability and progression of pathology that could explain the disease symptomology. With the advent of patient-derived cellular models and novel genetic manipulation tools we are now able to interrogate this commonality despite the cellular complexity of the brain in order to develop novel therapeutic strategies to prevent or arrest neurodegeneration. Here we describe broadly these concepts and their relevance across neurodegenerative diseases.

Keywords Neurodegeneration, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Frontotemporal Dementia, Trinucleotide repeat disorders, proteostasis, organelle trafficking, neuroinflammation, microglia, RNA metabolism, iPSCs, gene editing.

Introduction

Neurodegenerative diseases (NDD) are progressive disorders with increasing prevalence in our ageing population but with no cure or lasting symptomatic therapy. These include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), motor neuron disease (MND), Frontotemporal dementias (FTD) and Prion diseases. Over 45 million people worldwide live with dementia and up to 10million with Parkinson's disease. In the UK alone, 850,000 people are affected by dementia and 127,000 have Parkinson's disease. It is estimated that the number of patients with neurodegenerative brain diseases will increase to 131.5 million by 2050 (World Alzheimer Report 2015). With an estimated 160 billion Euros of costs of care annually in Europe alone and 818 billion dollars worldwide, this translates into a huge socio-economic burden. The need to understand the cellular and molecular mechanisms that underpin neurodegeneration has never been more urgent. Historically, these diseases have been studied in isolation as separate entities but recently a consensus has arisen that they share many common underlying mechanisms that can be exploited to identify novel therapeutic targets. Common cellular themes include misfolded protein handling, organelle trafficking, RNA processing, synaptic health and neuroinflammation. These cellular functions share overlapping molecular aetiologies. For example, misfolding of disease-specific proteins in AD, PD, HD or MND disrupt inter-organelle transport or degradation and impair synaptic neurotransmission whereas genome-wide association studies identified variants in inflammation-related genes across all these diseases. Therefore, delineating the shared underlying mechanisms that may counteract these cellular perturbations has become a major goal in understanding the molecular and cellular aetiology of NDD. How such mechanisms operate in the complex environment of neuronal connections and non-neuronal cells (e.g. microglia or the cerebral vasculature) to generate distinct patterns of cellular degeneration is becoming clearer from genetic and genome-wide association studies as well as better modelling and functional interrogation of gene networks. Nevertheless, it is important to recognise that each NDD also has its own distinct signature, e.g. deficits in nucleoprotein transport and RNA biology is a principal feature of MND whereas lysosomal defects is a major feature of PD. In this review article we provide an update on the broader concepts behind common themes across neurodegeneration that may be of interest to practicing clinicians caring for patients with NDD.

Pathology of protein misfolding

AD is associated with progressive deficits in memory, cognition and behaviour while PD is primarily considered a movement disorder. However, 30% AD sufferers develop parkinsonism and up to 80% of patients with PD for 20 years develop dementia ¹. This overlap extends to the primary molecular pathology of both diseases; AD is characterised by extracellular deposits of A β plaques and intracellular accumulations of tau neurofibrillary tangles distributed throughout the forebrain whereas PD is characterised by accumulation of α -synuclein in Lewy bodies (LBs) primarily within the dopaminergic neurons of the midbrain. However, LB are found in the amygdala of over half of patients diagnosed with AD and diffusely distributed in the cortex in Dementia with Lewy bodies (DLB) and patients with advanced PD, often alongside AD-type pathology ². Similarly, neuronal inclusions of TAR-DNA binding protein 43 (TDP-43) are found in motor neurons in MND ³ and cortical neurons in FTD but can also be detected alongside AD-type and LB pathology in up to a third of cases with mixed pathology ^{4,5}. Further evidence of common aetiology among NDD is provided by the overlap of underlying genetic contributors. For example, the ϵ 4 allele of the *APOE* gene is a strong genetic risk factor for both LB and AD-type pathology ^{6,7} and the microtubule-associated protein tau (*MAPT*) H1 haplotype is associated with both AD and PD ⁸. More recently, several loss-of-function variants in the ATP-binding cassette transporter A7 (*ABCA7*), which is involved in the clearance of protein aggregates have been associated with both AD and PD ⁹.

The strongest commonality between genetic and familial forms of the same NDD, as well as across different NDD, is the idea that misfolding of specific proteins leads to the generation of conformers with toxic gain-of-function inside or outside neurons that potentially spread to distant brain regions transynaptically or by other non-cell autonomous mechanisms ^{10,11}. Several genes that cause monogenic AD such as Amyloid Beta Precursor Protein (*APP*), presenilin1 (*PSEN1*), presenilin2 (*PSEN2*) as well as variants in the genome such as Phosphatidylinositol bonding clathrin assembly protein (*PICALM*) have mapped out the pathway of A β clearance and suggested that increased production and deposition of A β ₁₋₄₂ oligomers or fibrils in the brain of patients with sporadic AD may be the initiating pathogenic event ¹². Similarly, tau mutations were identified in familial cases of frontotemporal dementia and tau fibrils in neurofibrillary tangles is a cardinal feature of sporadic AD. α -Synuclein mutations or multiplications are rare causes of PD that share the

same pathology with sporadic PD, namely the misfolding of α -synuclein into LB ¹¹. In motor neuron disease, insoluble forms of phosphorylated and truncated TDP-43, normally a nuclear protein, accumulate in the cytosol of motor neurons ³ and bi-directionally transcribed repeat RNA in cases with hexanucleotide repeat expansion in *C9orf72* lead to the accumulation of dipeptide repeat proteins in dendritic inclusions in subpopulations of neurons of the motor cortex ¹³. In animal models, suppression of transgenic expression of APP, mutant tau, expanded huntingtin, TDP-43 or α -synuclein in mice was shown to arrest or even reverse pathological aggregates and phenotypic defects, supporting the notion that accumulation of these misfolded proteins is toxic whereas promoting their clearance could be beneficial ¹⁴⁻¹⁷. Although a toxic gain of function is a widely accepted mechanism in NDD, the precise physicochemical nature of the proteotoxic conformer has not been established but is generally considered to be a pre-fibrillar or fibrillar oligomer rather than the end-stage compact aggregates.

These pathological changes are thought to predate the clinical presentation by several years. For example, studies of a familial AD cohort [the Dominantly Inherited Alzheimer Network (DIAN)] suggest that A β ₁₋₄₂ levels in the cerebrospinal fluid (CSF) begin to decline as early as 25 years before the onset of symptoms ¹⁸. This is followed by the appearance of fibrillar amyloid deposits in the brain detected by PiB-PET, increased levels of tau in CSF, and progressive brain atrophy roughly 15 years before clinical presentation ¹⁸. Cerebral hypometabolism and subtle episodic verbal memory impairment seem to begin about 10 years before overt dementia ¹⁸. This time course may be generally similar to that of sporadic AD, based on cross-sectional studies ¹⁹ suggesting that detectable biochemical and histopathological abnormalities occur at least two decades before clinical symptoms. A similarly protracted pre-clinical course has also been suggested in PD, HD and MND.

The non-cell autonomous effects of fibrillar assemblies of A β ₁₋₄₂, tau and α -synuclein are reminiscent of “prion-like” phenomena. The strongest evidence that this may occur in human brain comes from the identification of LB pathology in embryonic neural grafts 12-16 years after transplantation into the brains of people with PD ^{20,21}. Direct inoculation of human brain extract or human brain-extracted fibrils from patients with LB pathology or multisystem atrophy led to progressive α -synuclein aggregation and neurodegeneration in connected areas of the brain of animal models including non-human primates ²²⁻²⁴. The propagation of α -synuclein in mouse brain has also been demonstrated with recombinant

fibrils but cell loss in this model was not always seen ^{22,25,26}. Similarly, tau pathology without neurodegeneration, was observed in wild-type or transgenic mice expressing human tau after seeding with fibrils extracted from human brain or mouse brain expressing the pathogenic P301S tau mutation ^{27,28}. Intracerebral infusion of dilute A β -rich brain extract from AD patients or from aged APP-transgenic mice also stimulated the premature formation of plaques and amyloid angiopathy in these models ²⁹. Induction of α -synuclein and tau aggregation in the brain has been demonstrated following intraperitoneal or intravascular injection of fibrils ^{27,28,30}. Propagation of misfolded SOD1 and TDP-43 was also reported in animal models of MND ^{31,32}.

Progress in identifying pathogenic proteins and their mode of propagation opened up the possibility for targeted therapies aimed at preventing their spread or promoting the clearance of their misfolded conformers. However, the most widely tested therapeutic approach to date, the use of active or passive immunotherapy, has not shown adequate clinical efficacy even though there was evidence in some trials that such approaches promote the clearance of A β ₁₋₄₂ ¹². A similarly poor response was detected in a larger trial that examined the effect of A β ₁₋₄₂ immunotherapy in a group of patients with mild AD-type dementia (EXPEDITION3). Whether such therapies need to be given at the pre-symptomatic phase of the disease to be effective is currently being investigated in around 300 presymptomatic members of a large Colombian pedigree with the *PSEN1* E280→A280 missense mutation and a smaller number of presymptomatic American participants from the DIAN cohort who carry other presenilin mutations. In contrast to the disappointing results in clinical end-points, immunotherapies in preclinical models effectively reduced the burden of extracellular amyloid plaques and this effect has also been observed in human cases that reached post-mortem ^{33,34}. The reason for this discrepancy is currently unclear but suggests that the complex cellular states of the human disease brain beyond the culprit protein need to be considered.

Proteostasis

One limitation of targeted therapies against misfolded proteins as exemplified by immunotherapies, is the assumption that during “degenerative” cellular states in the sporadic forms of these diseases, the neuronal mechanisms that normally handle misfolded proteins will rapidly recover and respond adequately to further protein aggregation, which *in*

vivo may occur over a period of hours ³⁵. Age-related deficiencies in protein homeostasis (proteostasis) ³⁶ could contribute to the accumulation of aggregating proteins (Figure 1). For example in AD or PD brains, there is upregulation of chaperones and accumulation of proteasomal and autophagic components ³⁷. Accumulation of misfolded proteins typically triggers the activation of chaperones, which either attempt to refold proteins or help redirect nonnative conformers towards degradation by proteasomes or lysosomes. Proteasomes are large multi-subunit complexes that consist of a 19S regulatory cap and a 20S proteolytic core, which together assembled into the 26S particle. The 19S regulatory particle recognizes ubiquitinated substrates, removes the ubiquitin chains, and unfolds the substrate to allow entry into the 20S core, where it is rapidly degraded into peptides ³⁸. Recent work has shown that phosphorylation of the 26S proteasome subunit Rpn6/PSMD11 by Protein Kinase A (PKA) increased the capacity of the proteasome to degrade a variety of substrates including proteins involved in NDD such as mutant forms of FUS, SOD1, TDP43 and tau ³⁹ and pharmacological activation of this mechanism with rolipram translated into reduced tau-mediated cognitive decline in a transgenic mouse model ⁴⁰. Although the proteasome is the primary source of protein degradation in the cell, restricted entry into the proteolytic chamber of the 20S component does not permit the degradation of misfolded or large protein complexes. One way to bypass this limitation is to employ chaperone complexes such as the BAG1-HSP70 or cytosolic valosin-containing protein/p97 that retrieve misfolded proteins from aggregates and then direct them to the proteasome. Supporting the central role of such pathways in NDD is the discovery of mutations in valosin-containing protein/p97 in rare forms of ALS and FTD ⁴¹. Alternatively, larger aggregates can be directed *en masse* to the lysosome via autophagy. Autophagy complements the proteasome in three forms: macroautophagy, chaperone-mediated autophagy (CMA), and selective ubiquitin-dependent autophagy. Macroautophagy is the best-understood form and entails the sequestration of organelles or aggregates into a double-membrane structure known as the autophagosome. The resulting autophagosome is then transported to, and fuses with, the lysosome, thereby delivering its cargo for degradation. In contrast, microautophagy occurs by direct engulfment of the cytosol at the lysosome membrane, and CMA occurs through HSC70-mediated delivery of proteins across the lysosomal membrane via the LAMP2A receptor ⁴².

Selective targeting of misfolded proteins to the proteasome or lysosome is initiated by the addition of polyubiquitin chains in a three-step enzymatic process involving E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes (E2s), and E3 ubiquitin ligases (E3s). Ubiquitin immunoreactivity is detected in all pathological inclusions across NDD suggesting a role for this modification in the handling of misfolded proteins ^{43,44}. The specificity of this system is determined by the existence of multiple E3/E2 pairs and the way they conjugate ubiquitin in chains: Certain conjugates (e.g. K11- and K48-linked chains) act as signals to the proteasome whereas others (e.g. K63-linked chains) mediate trafficking to the lysosome. These ubiquitin chains are in turn recognised by adaptor complexes, which direct the ubiquitinated proteins to the relevant pathway. The relevance of ubiquitin-dependent quality control is well established in PD especially in a subgroup of *familial* cases that are caused by mutations in the E3 ligases Parkin or FBXO7. In addition, mutations in the ubiquitin adaptors SQSTM1/p62 or optineurin cause familial MND/FTD whereas variants in BAG3 were linked to PD ^{45,46}.

One mechanism by which ubiquitin conjugating enzymes could mitigate toxicity in sporadic forms of NDD involves the direct ubiquitination and degradation of either monomeric or aggregated forms of pathogenic proteins as shown in reductionist systems and animal models. For example, the E3 ligase NEDD4 promotes whereas the deubiquitinase USP8 opposes the lysosomal clearance of α -synuclein and genetic modulation of these activities reduced α -synuclein toxicity ⁴⁷⁻⁵⁰. NEDD4 has been shown to have protective effects against TDP-43 and A β ⁵¹ that may be related to its broader effects on stress granule regulation or the activation of autophagy ^{52,53}. USP14 is a major regulator of protein turnover by the proteasome and its inhibition with small molecules accelerates the clearance of tau and TDP-43 ⁵⁴. Regulation of ubiquitination by USP19 has been implicated in the vesicular export of misfolded proteins at the endoplasmic reticulum (ER), that escape cytosolic degradation ⁵⁵. More broadly, ubiquitin homeostasis is critical for neuronal viability. For example, partial inactivation of the deubiquitinase UCH-L1, an enzyme that maintains free ubiquitin levels, leads to neurodegeneration ⁵⁶ and YOD1 in association with the AAA-ATPase p97 regulates the disposal of ruptured lysosomes and their content caused by tau fibrils ⁵⁷.

Impaired clearance of misfolded proteins may lead to their accumulation in the lumen of the endoplasmic reticulum (ER). These misfolded proteins are normally recognised by the ER membrane-associated complexes and retrotranslocated to the cytoplasm for

degradation by the valosin-containing protein/p97–NPL4–UFD-1 complex. In NDD, increased accumulation of misfolded proteins in the ER lumen induces ER stress and activates the Unfolded Protein Response (UPR). This is normally a protective cellular response that aims to reduce unfolded protein load and restore protein-folding homeostasis. The UPR has three arms, which initiate signalling cascades through protein kinase RNA (PKR)-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6). Paradoxically, persistent activation of the PERK-eIF2 α branch of the UPR is detrimental as it causes uncompensated decline in global translation rates leading to synaptic failure and neuronal death ⁵⁸. Restoring translation by targeting PERK or more selectively eIF2 α using repurposed drugs such as trazadone was neuroprotective and enhanced memory in animal models of prion disease and tauopathy despite the accumulation of misfolded proteins ⁵⁹.

Inter-organelle trafficking and organelle turnover

Defects in inter-organelle trafficking, especially endoplasmic reticulum (ER) to Golgi, endosomes to lysosomes and the turnover of lysosomes or mitochondria have emerged as critical events based on genetic and functional studies across NDD. For example, mutations in *VPS35*, a component of the retromer complex which functions in endosomal protein sorting cause late-onset forms of familial PD and AD ⁶⁰. Heterozygous mutations in the lysosomal enzyme glucocerebrosidase (GBA), which when biallelic cause Gaucher's disease, are the commonest risk factor for PD ⁶¹, at least partly by impairing the lysosomal degradation of α -synuclein ⁶². Mutations in the kinase *LRRK2*, which is the commonest form of autosomal dominant PD, impair endosomal trafficking and autophagy and are linked pathologically to the accumulation of both LB and neurofibrillary tangles ⁶⁰. Endosomal processing is also critical in the cleavage of APP and generation of A β ₁₋₄₂ or misfolded prions. *C9orf72*, a commonly mutated gene in MND and FTD, regulates vesicle trafficking via an interaction with the GTPase RAB7L1 ⁶³ and progranulin, which is haploinsufficient in FTD, regulates lysosome acidification and biogenesis ⁶⁴. The relevance of these pathways in sporadic NDD is reinforced by genome-wide linkage of variants in genes implicated in organelle trafficking with disease (e.g. *LRRK2*, *GAK* and *RAB7L* in PD and *PICALM* in AD).

Mitochondria provide a large proportion of ATP in the nervous system and also regulate intracellular Ca²⁺ homeostasis and the induction of apoptosis. Numerous studies in animal models showed that mitochondrial deficits are an early feature of diverse

proteinopathies associated with NDD ⁶⁵⁻⁶⁸, especially at the synapse, where synaptic mitochondria are subjected to the high-energy requirements associated with synaptic activity ^{68,69}. The relevance of mitochondria for healthy dopaminergic neuronal function in humans is supported by observations in methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) users who developed parkinsonism due to the conversion in astrocytes of MPTP to 1-methyl-4-phenylpyridinium (MPP⁺), which inhibits complex I of the electron transport chain in neurons. More broadly, respiratory chain defects due to mutations in components of Complex I to V (Leigh's syndrome) cause early onset diffuse neuronal loss pointing towards the critical role of oxidative phosphorylation for neuronal viability. In sporadic NDD, misfolded α -synuclein, oligomeric A β or mutant SOD1 were shown to bind to mitochondrial membranes and interfere with electron transport via interactions with Complex I or IV and the TOM complex which is responsible for the import of mitochondrial proteins ^{70,71}. Wild-type and mutant forms of TDP-43 were shown to gain access to the mitochondrial matrix and bind to mRNA encoding the Complex I subunits ND3 and ND6, impairing its assembly and function ⁷². Interactome analysis revealed that dipeptide repeat protein in neurons with repeat expansions in C9Orf72 preferentially bound to mitochondrial ribosomal proteins causing oxidative stress ⁷³. Mutant huntingtin may lead to mitochondria dysfunction via dysregulation of key transcription factors such as the CREB binding protein ^{67,74}. These examples serve to identify mitochondria as the recipients of cellular stressors but their dysfunction can ultimately amplify intracellular and non-cell autonomous signals that contribute to the progression of diverse pathologies via ATP reduction and release of reactive oxygen species or apoptotic signals. Accordingly, mechanisms of mitochondrial turnover are strong genetic determinants of dopaminergic neuronal death in certain forms of PD with homozygous mutations in *Pink1* or *Parkin* genes. In this pathway, dissipation of the mitochondrial membrane potential induces translocation of the kinase Pink1 to mitochondria and activation of Parkin through phosphorylation of ubiquitin and the ubiquitin-like domain of Parkin. This cascade initiates the degradation of mitochondrial proteins by the proteasome in a p97-dependent fashion or whole mitochondrial segments by autophagy (mitophagy) ⁷⁵. This pathway was shown to prevent dopaminergic degeneration in a mouse model of mitochondrial disease ⁷⁵ and may also serve broader protective effects as it also mitigates A β pathology *in vivo* ⁷⁶. It should be noted that parkin-independent mitophagy is also active in the nervous system ⁷⁷.

Neuroinflammation

Although neuroinflammation has long been considered a secondary event caused by neurodegeneration, recent genome-wide association studies and functional analyses in model systems suggest that microglia-related pathways are primary effectors in the pathogenesis of NDD ⁷⁸. Microglia are the resident macrophages of the central nervous system. They use classic immune molecules, such as complement proteins, to signal to neurons and glia, survey their microenvironment and refine the neuronal connectivity during development, in health and disease. Their role in neurodegeneration is strengthened by the association of mutations in genes that regulate immune signalling with NDD. A prominent example is TREM2, an innate immune receptor expressed on microglia and cells of the monocyte lineage. Human genetic studies identified rare mutations in TREM2 as a risk factor for AD and potentially PD and FTD ⁷⁹⁻⁸¹. TREM2 was shown to act as a negative regulator of inflammatory cytokine and Toll-like receptor (TLR) responses ⁸². Interestingly, TLR mediates the uptake of misfolded forms of α -synuclein and A β in microglia, which may represent an alternative non-cell autonomous mechanism for the progression of pathology ^{83,84}. Previous work showed that TREM2 helps sustain a microglial response around plaques that may function to contain toxic A β conformers and protect nearby neurites ^{85,86}. This work suggests that TREM2 signalling may be beneficial in responding to amyloid pathology, while variants leading to a loss of TREM2 function are detrimental. In contrast, lack of TREM2 in a mouse model of tauopathy was neuroprotective, reducing gliosis and neuroinflammation, which corresponded with preservation of brain volume without an effect on tau aggregation ⁸⁷. If confirmed, these data would suggest that the same microglial-related signalling mechanism has contrasting actions in NDD depending on the underlying proteinopathy.

Synaptic signals also influence microglia by activating cell surface receptors and modulating ion channels. In turn, perisynaptic microglia are able to sense early disruptions in synaptic activity and potentially contribute to synaptic demise. This process has been termed synaptic pruning, during which microglia connect with synapses using their highly motile processes and engulf the neuronal terminals ⁸⁸. One mechanism involved in this process is the classical complement cascade ^{89,90}. Region-specific synapse loss and dysfunction is an early hallmark of NDD. Complement proteins are often upregulated in NDD

and localise around areas of pathology, e.g. in neuritic plaques, along with microglia. C1q and C3 also associate with synapses before overt plaque deposition in multiple AD mouse models and localise to brain regions that are vulnerable to synapse loss ⁸⁹. In addition, microglia in adult mice engulf synaptic material in the presence of soluble oligomeric A β , in a complement receptor-dependent manner, and blocking the complement cascade protects the synapses from A β -induced loss ⁸⁹. Interestingly, complement activation and microglia-mediated synaptic pruning are also drivers of neurodegeneration caused by progranulin deficiency in mice ⁹¹ suggesting that similar mechanisms may be at play in other NDD.

RNA and neurodegeneration

Although most NDD result primarily from defects in protein function there is clear evidence that aberrant RNA processing is also a driver or contributing factor to the aetiology of neurodegeneration. Both coding and non-coding RNAs (including microRNAs and long ncRNAs) have been linked to NDD and all aspects of RNA metabolism have been implicated including splicing, stabilisation, and transport (Figure 2). The most prominent disease associated with defects in RNA biology is MND. Mutations in the RNA binding proteins TDP-43 ⁹²⁻⁹⁴ and FUS ^{95,96} cause familial MND, and mislocalisation of TDP-43 into cytoplasmic aggregates is a key pathogenic event in sporadic forms of the disease ⁹⁷. TDP-43 plays a role in several aspects of RNA processing, most notably regulation of splicing ⁹⁸⁻¹⁰¹ stability ¹⁰² and transport ¹⁰³. Although impaired TDP-43 and FUS mediated regulation of the splicing of thousands of coding and non-coding RNAs contribute to neurodegeneration, the identity of specific RNAs that are causatively linked to pathology is unknown. In addition to the effects of mutant TDP-43 and FUS on aberrant splicing, cytoplasmic aggregates and stress granules were also shown to cause the mislocalisation of other RNA binding proteins, causing further impairment on RNA processing ¹⁰⁴. More recently, aggregated and disease-linked mutant TDP-43 ¹⁰⁵ or RAN translated dipeptide repeat (DPR) proteins as observed C9orf72-related disease ¹⁰⁶, were shown to trigger the sequestration of nucleoporins interfering specifically with nuclear protein import and RNA export in *Drosophila* models, primary neurons and induced pluripotent stem cell-derived neurons from patients with TPD-43 with C9orf72-related mutations. Moreover, nuclear pore pathology was detected in brain tissue in cases of sporadic MND and those involving genetic mutations in TARDBP and C9orf72 ¹⁰⁵. These studies suggest that nucleocytoplasmic transport may be a common mechanism

linking protein aggregation and RNA metabolism in sporadic and familial forms of MND/FTD.

Evidence that RNA is a significant driver of neurodegeneration also comes from studies in trinucleotide repeat disorders ¹⁰⁷. The underlying common molecular aetiology of all such disorders is an unstable expansion of repetitive DNA, most commonly (CAG)_n, which when translated gives rise to a polyglutamine (PolyQ) tract that assembles into fibrillar intranuclear or cytoplasmic inclusions. Prominent examples include the CAG expansion in the first exon of the huntingtin gene (*HTT*) giving rise to HD and the CAG expansion in Ataxin 3 (*ATXN3*) giving rise to Spinocerebellar Ataxia type 3 (SCA3). The pathogenic role of RNA in SCA3 is supported by studies where interruption of the CAG expansion in *ATXN3* with CAA codons (encoding glutamine) that still retain the PolyQ expansion abrogate the toxicity in fly models whereas insertion of the CAG expansion into unrelated proteins led to toxicity ¹⁰⁸.

Perhaps the complexity of the role of RNA in neurodegeneration is most directly observed when considering ncRNAs, which by definition are not translated into any protein product. For example, Spinocerebellar ataxia type 8 is associated with a CAG expansion in the sense strand of *ATXN8* (Ataxin 8) gene and CTG expansion in the opposite strand, the latter giving rise to a CUG expansion in the *AXN8OS* (ataxin 8 opposite strand) antisense RNA ¹⁰⁹, suggesting that toxicity can arise from the presence of the *AXN8OS* in RNA foci ¹¹⁰ as well as expanded ATXN8 protein in nuclear inclusions ¹¹¹. A similar situation exists in Huntington's like 2 (HDL2) disease caused by CTG expansions in non-coding regions of the *Junctophilin-3* gene. As in SCA8, this results in a CAG expansion in an antisense transcript that is sufficient to cause the HD-like phenotype ¹¹². Several other mechanisms have been ascribed to toxic RNA repeats including interaction with RNA binding proteins, formation of intracellular RNA foci and epigenetic regulation ¹⁰⁷. These are not isolated contributory factors but more likely represent an interactive network linking repeat expansion in RNA and protein transcripts with toxicity.

Insights from new technologies

Until recently, the study of human neurons was largely confined to the histological characterization of end-stage disease in post-mortem brains. The advent of iPSC-based models has enabled dynamic studies in patient-derived neurons. Unlike immortalised human cell lines, iPSCs are derived from any personal genetic background and reprogrammed from a wide range of somatic cells including skin fibroblasts and hair follicle cells making it

possible to readily make patient-specific iPSCs. These, in turn, can be differentiated toward multiple neuronal and glial cell types relevant to individual NDD, associated with loss of specific neuronal populations such as cortical neurons in AD, medium spiny GABAergic neurons in HD and dopaminergic neurons in PD. There are now numerous studies in iPSC-based models with considerable heterogeneity in research practices and extent of maturity of such iPSC-derived cells. Nevertheless recent attempts to generate a phenogenetic on-line database (iPhemap) to catalogue disease phenotypes will greatly assist our search for and understanding of emerging common mechanisms across NDD ¹¹³. Phenotypic characterisation of iPSC-derived neurons from patients with monogenic forms of NDD, has reinforced the notion that neurons exhibit similar cellular defects. For example, iPSC-derived neurons expressing mutant forms of α -synuclein, tau, C9orf72 or expanded huntingtin have impaired mitochondrial function causing oxidative stress ^{49,114-116}. ER stress was observed in iPSC lines from patients with GBA-related PD ¹¹⁷, α -synuclein A53T mutation ⁴⁹ or triplication ¹¹⁸, C9orf72 ⁷³ and Tau A152T ¹¹⁶. Whether these changes reflect the generic state of an unhealthy neuron in the dish or a common downstream effector mechanism of neuronal vulnerability to different forms of proteotoxicity remains to be seen.

Gene editing now offers the possibility of introducing or reversing disease associated mutations or modulating the expression of modifiers ¹¹⁹. The most widely used CRISPR/Cas9 system ^{120,121} can be thought of as a dual module made up of a unique genomic address delivery system (provided by single-guide RNAs – sgRNAs) and an enzyme cargo (CRISPR associated protein 9 - Cas9 nuclease). The sgRNA binds to its unique complementary DNA sequence and delivers the Cas9 to a precise locus within the genome. The Cas9 nuclease then introduces double-stranded DNA breaks, which are subsequently repaired by endogenous DNA repair mechanisms and as a consequence introduces discrete mutations into the targeted locus. More recently, numerous engineered forms of Cas9 have been introduced that use Cas9 as a delivery vehicle without nuclease activity to either enhance or suppress gene expression. These tools have greatly expanded the repertoire of genomic and epigenomic changes including (i) reversion of specific disease-associated mutations, (ii) control of transcriptional activation or silencing, and (iii) manipulation of specific epigenetic marks ¹²². The combined power of iPSCs and gene-editing will facilitate the dissection of causative association from correlative ones.

Concluding remarks

Although a number of shared themes have been identified across NDD, it is likely that pathogenesis is not a linear cascade but rather a constellation of cellular pathways that define neuronal vulnerability and potentially gate the progression of pathology arising from different misfolded proteins. Nevertheless, the brain exhibits remarkable plasticity, which ensures that the myriad of its neuronal connections continue to function until a critical threshold is eventually reached. It is likely that a prolonged period of neuronal compensated dysfunction precedes cell loss. Identifying early stages on this neurodegenerative trajectory and delineating the druggable targets within such fundamental protein networks, will be key to developing future therapeutic interventions. In this respect, regulators of protein misfolding, inter-organelle trafficking or neuroinflammation are emerging as potential therapeutics across NDD.

Acknowledgements. GKT is funded by a Wellcome Trust Intermediate Clinical Fellowship (097479/Z/11/Z) and the Wellcome Beit Prize fellowship (097479/Z/11/A), European Union's Horizon 2020 research and innovation programme under grant agreement No.116060 (IMPRiND), ARUK, BMA, the Oxford Biomedical Research Centre and EPSRC (EP/M006204/1). The opinion expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.

Figure Legends

Figure 1: Proteostatic mechanisms against misfolded proteins. A central event in NDD is the misfolding of diverse proteins into toxic conformers with amyloid-like structure. Misfolded proteins that cannot be refolded by chaperones (HSP) are recognised by specialised complexes such as p97 at the Endoplasmic Reticulum (ER) surface or BAG1/HSC70 in the cytosol and targeted for degradation by the 26S proteasome in a ubiquitin (green dots) dependent fashion. Larger aggregates are targeted to the autophagosome, e.g. by BAG3/p62 or late endosome for degradation in the lysosome or egress via exosomes or related exocytic mechanisms. Large aggregates may escape

degradation and rupture the lysosomal membrane, causing the release of proteopathic seeds that template further aggregation of soluble monomeric protein. Misfolded proteins in the ER trigger the Unfolded Protein Response (UPR) that induces the transcription of chaperones and proteolytic pathways but if overactive can be detrimental to neurons. Misfolded proteins also impair mitochondrial function e.g. by interfering with the import mechanisms or respiratory complexes causing accumulation of reactive oxygen species (ROS), which in turn promote protein misfolding. Damaged mitochondria are cleared at least in part by Pink1/Parkin mediated mitophagy via ubiquitination of surface proteins.

Figure 2: RNA metabolism and neurodegeneration: RNA binding proteins such as TDP43 and FUS affect multiple levels of RNA metabolism including transcription (1), splicing (2), nucleocytoplasmic transport and stability (3) and localisation to stress granules (4). Mutations in *TARDP* and *FUS* can lead to errors in transcription, production of alternative transcripts and cellular stress all of which lead to neuronal death.

References

1. Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M. & Morris, J. G. L. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. *Mov. Disord.* **23**, 837–844 (2008).
2. Hamilton, R. L. Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α -Synuclein Immunohistochemistry. *Brain Pathology* 378–384 (2000).
3. Neumann, M. *et al.* Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* **314**, 130–133 (2006).
4. Uryu, K. *et al.* Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. *J. Neuropathol. Exp. Neurol.* **67**, 555–564 (2008).
5. Nakashima-Ysuka, H, *et al.* Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. *Acta Neuropathol* **114**, 221-229 (2017).
6. Lippa, C.F. *et al.* Apolipoprotein E genotype and Lewy body disease. *Neurology* **45**, 97-103.
7. Saunders, A.M. *et al.* Apolipoprotein ϵ 4 allele distributions in late-onset Alzheimer's disease and other amyloid forming diseases. *Lancet* **342**, 710-711 (1993)
8. Shulman, J. M. & De Jager, P. L. Evidence for a common pathway linking neurodegenerative diseases. *Nat Genet* **41**, 1261–1262 (2009).
9. Nuytemans, K. *et al.* Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants. *Neurol Genet* **2**, e44 (2016).
10. Goedert, M., Eisenberg, D. S. & Crowther, R. A. Propagation of Tau Aggregates and Neurodegeneration. *Annu. Rev. Neurosci.* **40**, 189–210 (2017).
11. Tofaris, G. K., Goedert, M. & Spillantini, M.-G. The Transcellular Propagation and Intracellular Trafficking of α -Synuclein. *Cold Spring Harb Perspect Med* **7**, a024380 (2017).
12. Selkoe, D. J. Preventing Alzheimer's disease. *Science* **337**, 1488–1492 (2012).
13. Saberi, S. *et al.* Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. *Acta Neuropathol* **122**, 691–16 (2017).
14. Jankowsky, J. L. *et al.* Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. *PLoS Med* **2**, e355 (2005).
15. Santacruz, K. *et al.* Tau suppression in a neurodegenerative mouse model improves memory function. *Science* **309**, 476–481 (2005).
16. Lim, Y. *et al.* α -Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. *J. Neurosci.* **31**, 10076–10087 (2011).
17. Walker, A. K. *et al.* Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. *Acta Neuropathol* **130**, 643–660 (2015).
18. Bateman, R. J. *et al.* Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N Engl J Med* **367**, 795–804 (2012).
19. Jack, C. R. *et al.* Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *The Lancet Neurology* **9**, 119–128 (2010).
20. Li, J.-Y. *et al.* Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. *Nat Med* **14**, 501–503 (2008).
21. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. *Nat Med* **14**, 504–506 (2008).
22. Masuda-Suzukake, M. *et al.* Prion-like spreading of pathological α -synuclein in brain. *Brain* **136**, 1128–1138 (2013).
23. Recasens, A. *et al.* Lewy body extracts from Parkinson disease brains trigger α -

- synuclein pathology and neurodegeneration in mice and monkeys. *Ann Neurol*. **75**, 351–362 (2014).
24. Prusiner, S. B. *et al.* Evidence for α -synuclein prions causing multiple system atrophy in humans with parkinsonism. *Proc. Natl. Acad. Sci. U.S.A.* **112**, E5308–17 (2015).
 25. Luk, K. C. *et al.* Pathological α -synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science* **338**, 949–953 (2012).
 26. Osterberg, V. R. *et al.* Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. *Cell Rep* **10**, 1252–1260 (2015).
 27. de Calignon, A. *et al.* Propagation of tau pathology in a model of early Alzheimer's disease. *Neuron* **73**, 685–697 (2012).
 28. Clavaguera, F. *et al.* Transmission and spreading of tauopathy in transgenic mouse brain. *Nat Cell Biol* **11**, 909–913 (2009).
 29. Meyer-Luehmann, M. *et al.* Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. *Science* **313**, 1781–1784 (2006).
 30. Peelaerts, W. *et al.* α -Synuclein strains cause distinct synucleinopathies after local and systemic administration. *Nature* **522**, 340–344 (2015).
 31. Iguchi, Y. *et al.* Exosome secretion is a key pathway for clearance of pathological TDP-43. *Brain* **139**, 3187–3201 (2016).
 32. Münch, C., O'Brien, J. & Bertolotti, A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 3548–3553 (2011).
 33. Nicoll, J. A. R. *et al.* Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. *Nat Med* **9**, 448–452 (2003).
 34. Masliah, E. *et al.* Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. *Neurology* **64**, 129–131 (2005).
 35. de Calignon, A. *et al.* Caspase activation precedes and leads to tangles. *Nature* **464**, 1201–1204 (2010).
 36. Labbadia, J. & Morimoto, R. I. The biology of proteostasis in aging and disease. *Annu. Rev. Biochem.* **84**, 435–464 (2015).
 37. Nixon, R. A. The role of autophagy in neurodegenerative disease. *Nat Med* **19**, 983–997 (2013).
 38. Goldberg, A. L. Protein degradation and protection against misfolded or damaged proteins. *Nature* **426**, 895–899 (2003).
 39. Lokireddy, S., Kukushkin, N. V. & Goldberg, A. L. cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. *Proc. Natl. Acad. Sci. U.S.A.* **112**, E7176–85 (2015).
 40. Myeku, N. *et al.* Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. *Nat Med* **22**, 46–53 (2016).
 41. Watts, G. D. J. *et al.* Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. *Nat Genet* **36**, 377–381 (2004).
 42. Rubinsztein, D. C. The roles of intracellular protein-degradation pathways in neurodegeneration. *Nature* **443**, 780–786 (2006).
 43. Lowe, J. *et al.* Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. *J. Pathol.* **155**, 9–15 (1988).
 44. Tofaris, G. K., Razzaq, A., Ghetti, B., Lilley, K. S. & Spillantini, M.-G. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. *Journal of Biological Chemistry* **278**, 44405–44411 (2003).

45. Goode, A. *et al.* Defective recognition of LC3B by mutant SQSTM1/p62 implicates impairment of autophagy as a pathogenic mechanism in ALS-FTLD. *Autophagy* **12**, 1094–1104 (2016).
46. Chang, D. *et al.* A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nature Publishing Group* **91**, 1–10 (2017).
47. Tofaris, G. K. *et al.* Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 17004–17009 (2011).
48. Davies, S. E. *et al.* Enhanced ubiquitin-dependent degradation by Nedd4 protects against α -synuclein accumulation and toxicity in animal models of Parkinson's disease. *Neurobiology of Disease* **64**, 79–87 (2014).
49. Chung, C. Y. *et al.* Identification and rescue of α -synuclein toxicity in Parkinson patient-derived neurons. *Science* **342**, 983–987 (2013).
50. Alexopoulou, Z. *et al.* Deubiquitinase Usp8 regulates α -synuclein clearance and modifies its toxicity in Lewy body disease. *Proc. Natl. Acad. Sci. U.S.A.* **113**, E4688–97 (2016).
51. Khurana, V. *et al.* Genome-Scale Networks Link Neurodegenerative Disease Genes to α -Synuclein through Specific Molecular Pathways. *Cell Systems* (2017). doi:10.1016/j.cels.2016.12.011
52. Zhou, Z., Kawabe, H., Suzuki, A., Shinmyozu, K. & Saga, Y. NEDD4 controls spermatogonial stem cell homeostasis and stress response by regulating messenger ribonucleoprotein complexes. *Nature Communications* **8**, 15662 (2017).
53. Sun, A. *et al.* The E3 ubiquitin ligase NEDD4 is an LC3-interactive protein and regulates autophagy. *Autophagy* **13**, 522–537 (2017).
54. Lee, B. H. *et al.* Enhancement of proteasome activity by a small molecule inhibitor of USP14. *Nature* **467**, 179–184 (2010).
55. Lee, J.-G., Takahama, S., Zhang, G., Tomarev, S. I. & Ye, Y. Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. *Nat Cell Biol* **18**, 765–776 (2016).
56. Saigoh, K. *et al.* Intragenetic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. *Nature Genet* **23**, 47–51.
57. Papadopoulos, C. *et al.* VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy. *EMBO J* **36**, 135–150 (2017).
58. Moreno, J. A. *et al.* Sustained translational repression by eIF2 α -P mediates prion neurodegeneration. *Nature* **485**, 507–511 (2012).
59. Halliday, M. *et al.* Repurposed drugs targeting eIF2 α -P-mediated translational repression prevent neurodegeneration in mice. *Brain* **140**, 1768–1783 (2017).
60. Perrett, R. M., Alexopoulou, Z. & Tofaris, G. K. The endosomal pathway in Parkinson's disease. *Mol. Cell. Neurosci.* **66**, 21–28 (2015).
61. Sidransky, E. *et al.* Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *N Engl J Med* **361**, 1651–1661 (2009).
62. Mazzulli, J. R. *et al.* Gaucher disease glucocerebrosidase and α -synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell* **146**, 37–52 (2011).
63. Aoki, Y. *et al.* C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. *Brain* **140**, 887–897 (2017).
64. Tanaka, Y. *et al.* Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. *Human Molecular Genetics* **26**, 969–988 (2017).
65. la Monte, de, S. M., Luong, T., Neely, T. R., Robinson, D. & Wands, J. R. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. *Lab. Invest.* **80**, 1323–1335 (2000).
66. Swerdlow, R. H. & Khan, S. M. A 'mitochondrial cascade hypothesis' for sporadic Alzheimer's disease. *Med. Hypotheses* **63**, 8–20 (2004).
67. Panov, A. V. *et al.* Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. *Nat Neurosci* **5**, 731–736 (2002).
68. Du, H. *et al.* Early deficits in synaptic mitochondria in an Alzheimer's disease mouse

- model. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 18670–18675 (2010).
69. Wang, L. *et al.* Synaptosomal Mitochondrial Dysfunction in 5xFAD Mouse Model of Alzheimer's Disease. *PLoS ONE* **11**, e0150441 (2016).
 70. Di Maio, R. *et al.* α -Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. *Science Translational Medicine* **8**, 342ra78–342ra78 (2016).
 71. Pera, M. *et al.* Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. *EMBO J* e201796797 (2017). doi:10.15252/embj.201796797
 72. Wang, W. *et al.* The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. *Nat Med* **22**, 869–878 (2016).
 73. Lopez-Gonzalez, R. *et al.* Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. *Neuron* **92**, 383–391 (2016).
 74. Sugars, K. L. & Rubinsztein, D. C. Transcriptional abnormalities in Huntington disease. *Trends Genet.* **19**, 233–238 (2003).
 75. McWilliams, T. G. & Muqit, M. M. PINK1 and Parkin: emerging themes in mitochondrial homeostasis. *Curr Opin Cell Biol* **45**, 83–91 (2017).
 76. Du, F. *et al.* PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease. *Brain* (2017). doi:10.1093/brain/awx258
 77. McWilliams, T. G. *et al.* Basal Mitophagy Occurs Independently of PINK1 in Mouse Tissues of High Metabolic Demand. *Cell Metab.* (2018). doi:10.1016/j.cmet.2017.12.008
 78. Lambert, J.-C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452–1458 (2013).
 79. Guerreiro, R. *et al.* TREM2 variants in Alzheimer's disease. *N Engl J Med* **368**, 117–127 (2013).
 80. Jonsson, T. *et al.* Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med* **368**, 107–116 (2013).
 81. Rayaprolu, S. *et al.* TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. *Mol Neurodegeneration* **8**, 19 (2013).
 82. Colonna, M. TREMs in the immune system and beyond. *Nat. Rev. Immunol.* **3**, 445–453 (2003).
 83. Tahara, K. *et al.* Role of toll-like receptor signalling in Abeta uptake and clearance. *Brain* **129**, 3006–3019 (2006).
 84. Kim, C. *et al.* Neuron-released oligomeric α -synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. *Nature Communications* **4**, 1562 (2013).
 85. Wang, Y. *et al.* TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. *J. Exp. Med.* **213**, 667–675 (2016).
 86. Yuan, P. *et al.* TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. *Neuron* **92**, 252–264 (2016).
 87. Leyns, C. E. G. *et al.* TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. *Proc. Natl. Acad. Sci. U.S.A.* **114**, 11524–11529 (2017).
 88. Hong, S. & Stevens, B. Microglia: Phagocytosing to Clear, Sculpt, and Eliminate. *Developmental Cell* **38**, 126–128 (2016).
 89. Hong, S. *et al.* Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* (2016). doi:10.1126/science.aad8373
 90. Stevens, B. *et al.* The classical complement cascade mediates CNS synapse elimination. *Cell* **131**, 1164–1178 (2007).
 91. Lui, H. *et al.* Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. *Cell* **165**, 921–935 (2016).
 92. Gitcho, M. A. *et al.* TDP-43 A315T mutation in familial motor neuron disease. *Ann*

- Neurol.* **63**, 535–538 (2008).
93. Kabashi, E. *et al.* TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat Genet* **40**, 572–574 (2008).
 94. Sreedharan, J. *et al.* TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science* **319**, 1668–1672 (2008).
 95. Kwiatkowski, T. J. *et al.* Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science* **323**, 1205–1208 (2009).
 96. Vance, C. *et al.* Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. *Science* **323**, 1208–1211 (2009).
 97. Van Deerlin, V. M. *et al.* TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. *The Lancet Neurology* **7**, 409–416 (2008).
 98. Buratti, E. *et al.* Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. *EMBO J* **20**, 1774–1784 (2001).
 99. Ling, J. P., Pletnikova, O., Troncoso, J. C. & Wong, P. C. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. *Science* **349**, 650–655 (2015).
 100. Shiga, A. *et al.* Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. *PLoS ONE* **7**, e43120 (2012).
 101. Tollervey, J. R. *et al.* Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. *Nat Neurosci* **14**, 452–458 (2011).
 102. Liu, X., Li, D., Zhang, W., Guo, M. & Zhan, Q. Long non-coding RNA gadd7 interacts with TDP-43 and regulates Cdk6 mRNA decay. *EMBO J* **31**, 4415–4427 (2012).
 103. Costessi, L., Porro, F., Iaconcig, A. & Muro, A. F. TDP-43 regulates β -adducin (Add2) transcript stability. *RNA Biol* **11**, 1280–1290 (2014).
 104. Murakami, T. *et al.* ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. *Neuron* **88**, 678–690 (2015).
 105. Chou, C.C. *et al.* TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. *Nat Neurosci.* (2018) doi: 10.1038/s41593-017-0047-3
 106. Freibaum *et al.* GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic protein transport. *Nature* **525**, 129–133 (2015)
 107. Polak, U., McIvor, E., Dent, S. Y. R., Wells, R. D. & Napierala, M. Expanded complexity of unstable repeat diseases. *Biofactors* **39**, 164–175 (2013).
 108. Li, L.-B., Yu, Z., Teng, X. & Bonini, N. M. RNA toxicity is a component of ataxin-3 degeneration in *Drosophila*. *Nature* **453**, 1107–1111 (2008).
 109. Mutsuddi, M., Marshall, C. M., Benzow, K. A., Koob, M. D. & Rebay, I. The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with stau1 in *Drosophila*. *Curr. Biol.* **14**, 302–308 (2004).
 110. Koob, M. D. *et al.* An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). *Nat Genet* **21**, 379–384 (1999).
 111. Moseley, M. L. *et al.* Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. *Nat Genet* **38**, 758–769 (2006).
 112. Wilburn, B. *et al.* An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. *Neuron* **70**, 427–440 (2011).
 113. Hollingsworth, E. W. *et al.* iPhemap: an atlas of phenotype to genotype relationships of human iPSC models of neurological diseases. *EMBO Mol Med* e201708191 (2017). doi:10.15252/emmm.201708191
 114. Israel, M. A. *et al.* Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* **482**, 216–220 (2012).
 115. Dafinca, R. *et al.* C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in

- Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. *STEM CELLS* **34**, 2063–2078 (2016).
116. Silva, M. C. *et al.* Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability. *Stem Cell Reports* **0**, (2016).
 117. Fernandes, H. J. R. *et al.* ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α -Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons. *Stem Cell Reports* **6**, 342–356 (2016).
 118. Heman-Ackah, S. M. *et al.* Alpha-synuclein induces the unfolded protein response in Parkinson's disease SNCA triplication iPSC-derived neurons. *Human Molecular Genetics* **26**, 4441–4450 (2017).
 119. Sandoe, J. & Eggan, K. Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. *Nature Publishing Group* **16**, 780–789 (2013).
 120. Jinek, M. *et al.* A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* **337**, 816–821 (2012).
 121. Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. *Science* **346**, 1258096–1258096 (2014).
 122. Thakore, P. I., Black, J. B., Hilton, I. B. & Gersbach, C. A. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. *Nature Publishing Group* **13**, 127–137 (2016).